Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-07-19 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于调整2022年限制性股票激励计划限制性股票授予价格的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the adjustment of the grant price of restricted stock under the 2022 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and the rationale for adjusting the stock grant price due to dividend distribution. The document is a formal disclosure about changes to an existing stock incentive plan, specifically the adjustment of the restricted stock grant price. It does not contain financial statements, earnings data, or comprehensive financial performance analysis. It is not a full annual or interim report, nor is it a call transcript or audit report. The content is focused on management decisions and disclosures related to stock incentives, which aligns with announcements about capital changes or share issues. Given the nature of the announcement about adjusting the restricted stock grant price, it fits best under the category of Share Issue/Capital Change (SHA). The document length is 3400 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is SHA with high confidence.
2024-07-19 Chinese
长春百克生物科技股份公司关于控股股东和持股 5%以上股东、董事、总经理自愿承诺未来六个月内不减持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Changchun Baike Biotechnology Co., Ltd. regarding a voluntary commitment by the controlling shareholder and shareholders holding more than 5% of shares, as well as the director and general manager, not to reduce their shareholdings within the next six months. It includes specific shareholding percentages and a commitment period. This type of announcement relates to significant shareholding notifications or shareholder commitments rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial data, nor is it a report or presentation. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding commitments, confirming this classification with high confidence.
2024-06-24 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings
2024-06-14 Chinese
长春百克生物科技股份公司首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period expiration, shareholder commitments, and regulatory compliance confirmations. It references regulatory approvals and includes a verification opinion from the sponsoring securities firm. The document length is 3312 characters, which is relatively short and focused on a specific event rather than a comprehensive financial report. It does not contain financial statements or detailed financial analysis but rather announces the unlocking and circulation of restricted shares. This fits the definition of a Share Issue/Capital Change announcement (SHA), as it concerns the change in share capital availability due to the expiration of lock-up periods and the listing of previously restricted shares.
2024-06-14 Chinese
长春百克生物科技股份公司关于参加网上集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in an online collective earnings explanation meeting organized by securities associations. It mentions the date and time of the event, the platform for investor interaction, and the presence of company executives for Q&A regarding 2023 operating performance. The document does not contain actual financial statements or detailed financial data, nor is it a transcript of the event. It is essentially a notice about an upcoming earnings-related investor presentation. Therefore, it fits best as an Investor Presentation (IP) announcement rather than an earnings release or report itself.
2024-05-20 Chinese
长春百克生物科技股份公司关于更换持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's continuous supervision sponsor representatives. It details the replacement of a sponsor representative due to work adjustments and provides the new representative's resume. There is no financial data, no report attached or referenced as being published, and no mention of voting results or management changes beyond the sponsor representative role. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a procedural change related to the company's IPO supervision, not a full management change or financial report.
2024-05-16 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.